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GENERAL INTRODUCTION 
Heart disease is the leading cause of human death in the 
united states, accounting for nearly 40 percent of the annual 
deaths (National Research Council, 1989; u.s. Department of 
Health and Human services, 1988). An increasing amount of the 
medical literature has documented the relationship between 
concentrations of serum cholesterol and risk of heart disease 
in men and to a smaller extent in women. populations from 
developed countries, which consume diets high in meat and low 
in fiber, a much greater risk for coronary artery disease than 
are more rural populations. It has been proven that dietary 
cholesterol, fat, protein, carbohydrate, fibers, minerals, and 
vitamins can affect the concentration of plasma cholesterol. 
Diet plays an important role in the control of 
hypercholesterolemia. Amount of fat ingested can affect 
concentration of plasma cholesterol; high fat diet increase 
the incidence of hypercholesterolemia, whereas low fat diets 
decrease the incidence (Groot and Scheek, 1984). Decrease in 
dietary lipids containing saturated fatty acids and 
cholesterol is a basic precaution that is recommended for the 
prevention, arrest, and reversal of atherosclerosis. 
Several processes to decrease the cholesterol 
concentration in various food products have been proposed. 
Cholesterol reductase, an enzyme that converts cholesterol to 
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poorly absorbed coprostanol, shows promise for 
"decholesterolizing" meat, egg, and dairy products. 
A primary reaction of intestinal bacteria on neutral 
steroids is the conversion of cholesterol to coprostanol. This 
reaction results in reduction of the 5-6 double bond of 
cholesterol to form the saturated derivative coprostanol that 
is absorbed poorly in humans (Bhattacharyya, 1986). Eyssen et 
ale (1973) identified Eubacterium ATCC 21,408 as an intestinal 
gram-positive anaerobe that was capable of reducing 
cholesterol to coprostanol. This organism now has been 
isolated from the feces of humans, baboons, and rats 
(Macdonald et al., 1983). 
The conversion of cholesterol into coprostanol by 
intestinal microorganisms has been reported to occur by means 
of two different pathways. One pathway involves a direct 
reduction of the double bound at C-5 (Rosenfeld et al., 1954; 
Rosenfeld and Gallagher, 1964): the other involves the 
intermediate formation of 4-cholesten-3-one and coprostanone 
(Bjorkhem and Gustafsson, 1971). Coprostanol produced by 
incubating Eubacterium ATCC 21,408 with [4,8_3H, 4_14C]-
cholesterol had retained 81% of the tritium originally present 
in cholesterol, most of which had been transfered to the C-6 
position in coprostanol, indicating that the conversion of 
cholesterol in coprostanol involved isomerization of a 5-6 
double bond to a 4-5 double bond and an intramolecular shift 
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of the major amount of tritium from C-4 to C-6 (Parmentier and 
Eyssen, 1973). 
Recently, my colleagues isolated a pure culture of a 
cholesterol-reducing microorganism from a swine sewage lagoon. 
This bacterium classified as Eubacterium sp. strain HL 
converts cholesterol into coprostanol in the incubation media 
to greater than 90%. The present investigation was designed to 
elucidate the pathways of biohydrogenation of cholesterol by 
Eubacterium sp. strain HL. 
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EXPLANATION OF THESIS FORMAT 
This thesis has been prepared according to the alternate 
thesis format as described in the Iowa state University 
Graduate College Thesis Manual. Results of research completed 
to partially complete requirements for the Master of Science 
degree are contained within the thesis. The thesis contains a 
review of the literature and an introduction to the problem, 
as well as materials and methods, results and discussion 
sections, and is in a form suitable for publication in a 
scientific journal. 
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LITERATURE REVIEW 
Atherosclerosis 
Atherosclerosis and its complications are the main cause 
of death in civilized countries. Elements of atherosclerosis 
are present in all arteries, young or old, animal or human. 
It is well established that atherosclerosis is a 
multifactorial disease and that both genes and environment 
contribute to its development (Davignon et al., 1977). 
However, many complex and numerous cellular factors are 
involved in atherogenesis. The end product remains primarily 
the accumulation of cholesterol and cholesterol esters in the 
intima of the arterial wall at vulnerable sites. Fatty 
deposits in the interior of arteries contain 70% cholesterol 
(Linder, 1985). Many studies have shown that in groups of 
humans whose concentrations of blood cholesterol are high the 
incidence of atherosclerosis also is high (Hulley, 1988). 
Dietary studies in man have produced much evidence to support 
this relationship. Numerous studies have shown that excess 
dietary cholesterol has an undeniable hypercholesterolemic 
effect and induces atherosclerosis (Page, 1954). Furthermore, 
it was initially thought that man's maximal daily absorption 
of dietary cholesterol, despite variable dietary intake, could 
not exceed 300-500 mg per day (Kaplan et al., 1963; Wilson et 
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al., 1965). It is now clear that the amount of cholesterol 
absorbed varies directly with amounts of cholesterol intake 
(Borgstrom, 1969; Quintao et al., 1971). A drastic lowering of 
cholesterol intake (from 600 mg/day to less than 50 mg/day) 
will decrease plasma cholesterol from 15% to 20% in human. 
(Connor, 1980). 
Because cholesterol of an atherosclerotic lesion 
originates in large part from blood plasma, much attention has 
been focused on the interaction between lipoproteins and 
arterial epithelial cells. Research on the etiology of 
atherosclerosis received a new impetus when it was suggested 
that low-density lipoproteins (LOL) and high-density 
lipoproteins (HOL) play opposite roles in cholesterol 
deposition during lesion development (Kannel at al., 1979). 
Studies suggested that LDL are associated positively with 
atherosclerosis and HOL do not seem to be associated with 
atherosclerosis (Small, 1977). The concentration of 
circulating LOL is related directly to the consumption of 
cholesterol and saturated fats (American Heart Association 
Nutrition Committee, 1982). Furthermore, when either 
monounsaturated or polyunsaturated dietary fats are 
substituted for saturated dietary fats, plasma cholesterol 
concentration decreases (American Heart Association Nutrition 
Committee, 1982). 
Even though numerous studies have been done, the 
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mechanism of atherogenesis still remains unclear. At least 37 
different variables have been correlated with atherosclerosis 
(strasser, 1972). Hypercholesterolemia, hypertension, and 
cigarette smoking have the strongest positive correlation to 
premature coronary heart disease (Gordon et al., 1971). 
Cholesterol Ketabolism 
For many years, the metabolism of cholesterol has been a 
subject of great interest. Cholesterol is a necessary body 
substance that is found in all animal tissues. It is the 
precursor of steroid hormones and bile acids, and a major 
constituent of atherosclerotic plaques and most gallstones. 
Much has been learned about cholesterol metabolism in both 
animals and man during the last 20 years. Interestingly, the 
adrenal gland contains a relatively high concentration of 
cholesterol that is depleted rapidly under stress when 
cortical activity is high (Pike, 1975). Adipose tissue is a 
major cholesterol storage organ (Farkas et al., 1973). 
Cholesterol in the blood stream comes from two sources: 
firstly, cholesterol is produced naturally by the body's cells 
at about 700-900 mg per day. Secondly, cholesterol in blood is 
derived from the intake of cholesterol-containing foods at 
about 300 to 500 0 mg per day in man (Turley and Dietschy, 
1982). 
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Absorption of cholesterol 
The average American diet supplies approximately 400 to 
700 mg of cholesterol per day. Intestinal cholesterol, 
however, is derived not only from the diet but also from 
intestinal secretions and bile. Bile usually transports from 
750 to 1250 mg cholesterol per day (Bennion and Grundy, 1975); 
the contribution from the sloughed mucosal cells is 
significantly less. Most of the cholesterol in bile is 
unesterified, but a portion of dietary cholesterol may be 
esterified with fatty acids (Grundy, 1983). Any cholesterol 
ester entering the intestinal lumen is de-esterified rapidly 
by pancreatic cholesterol esterase (Sabine, 1977). Free 
cholesterol must be solubilized before absorption. This 
cholesterol solubilization is achieved by its incorporation 
into mixed micelles containing conjugated bile acids, fatty 
acids, monoacyglycerols, and lysolecithin (Hofmann and 
Borgstrom, 1964). Efficiency of cholesterol absorption is 
limited; only from 30% to 60% of dietary and biliary 
cholesterol is absorbed (Grundy and Mok, 1977). Increasing the 
cholesterol intake results in increased total absorption, 
although the percentage absorbed is usually lower. Passage 
through the lipid of the mucosal cell membrane occurs by a 
passive diffusion. In the mucosal cell, cholesterol is re-
esterified largely with unsaturated fatty acids, incorporated 
into chylomicrons, and transferred into intestinal lymph. 
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Dietary cholesterol absorption may be affected by the 
amount of biliary cholesterol released into the intestine. 
Evidence shows that biliary cholesterol is absorbed similarly 
to that of dietary cholesterol but is absorbed more 
efficiently than the dietary cholesterol as a result of a 
difference in the physical state of the cholesterol (Grundy, 
1983). Biliary cholesterol enters the intestine in micellar 
solution, whereas dietary cholesterol must be digested and 
transformed into a micellar state before absorption. This 
transformation of dietary cholesterol usually is not 100% 
efficient. Absorption of endogenous cholesterol ranges between 
60 and 80% (Grundy and Mok, 1977), but absorption of dietary 
cholesterol usually is lower and varies from 20 to 80% 
(Grundy, 1979). 
Degradation of cholesterol 
The regulation of blood cholesterol concentration depends 
not only on the rate of de novo synthesis but also on the rate 
of degradation and excretion of cholesterol. Some cholesterol 
is excreted into the bile, a portion of which may be 
reabsorbed from the intestine. Some biliary cholesterol is 
reduced by bacteria in the digestive tract to coprostanol and 
coprostanone, which are excreted in the feces along with 
unabsorbed cholesterol (Dietschy and Wilson, 1970). 
The main disposal mechanism for excess body cholesterol 
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is by way of metabolism to bile acids. Conversion of 
cholesterol to bile acids occurs primarily in the liver (Salen 
and Shefer, 1983). Bile acids, which are synthesized de novo 
in the liver, are called primary bile acids, whereas secondary 
bile acids are formed from the metabolism of the primary bile 
acids by "intestinal microorganisms. The two most abundant 
primary bile acids in humans, cholic acid and chenodeoxycholic 
acid, are synthesized in the liver from cholesterol (Bergstrom 
et al., 1960). These acids are conjugated with taurine or 
glycine and appear in the bile as the sodium or potassium 
salts (Sabine, 1977). The conjugated bile acids excreted with 
bile enter into the gastrointestinal tract and are transformed 
by microorganisms into secondary bile acids, such as 
deoxycholic and lithocholic acids. Most bile acids are 
reabsorbed rapidly and return to the liver via the portal 
circulation where they are further metabolized and are 
resecreted into bile. Only a small daily turnover of bile 
acids through the intestine and into the feces occurs 
(Dietschy and Wilson, 1979). In humans, approximately 20-30 g 
of bile salts are secreted by the liver but only about 0.5 g 
appears in the feces each day (Zubay, 1988). 
Reduction of cholesterol to coprostanol 
Unabsorbed cholesterol is eliminated ultimately from the 
body in the feces as fecal neutral steroids. The fecal neutral 
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sterols represent a mixture of derivatives of endogenous 
cholesterol and a varying amount of unabsorbed dietary sterols 
of animal and vegetable origin (Gould and Cook, 1958). The 
fecal neutral steroids of rats originate primarily from three 
sources: 1. de novo cholesterol synthesis by the intestinal 
mucosa and liver, 2. dietary and mucosal sterols, and 3. a 
rapidly exchangeable cholesterol pool excreted through bile, 
the intestinal wall, or both (Miettinen et al., 1981). It is 
possible that fecal neutral sterols are derived predominantly 
from dietary and intestinal origin rather than from 
homogeneous lumenal pool derived from the diet, the bile, and 
the intestinal wall (Wilson and Reinke, 1968). 
During intestinal transit, cholesterol is converted 
mainly into two bacterial conversion products, coprostanol and 
coprostanone (McNamara et al., 1981). Cholesterol, 
coprostanol, and coprostanone accounts for more than 95% of 
the neutral steroid in human feces; the remainder is 
predominantly cholestanol. Depending upon the diet, 50% or 
more of the total fecal sterol can be present in the form of 
coprostanol (Heftman, 1970). In addition, evidence was 
obtained for the presence in human feces of trace amounts of 
epicoprostanol and cholestanone (McNamara et al., 1981). The 
early observations that mixed fecal cultures of human or rat 
readily transform cholesterol to coprostanol led to later 
attempts to isolate the microorganisms responsible for this 
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transformation (Snog-kjaer et al., 1956). The microorganisms 
responsible for these transformations were identified as 
Eubacterium species (Eyssen, 1973; Sadzikowski et al., 1977). 
Eyssen et al. (1973) reported that the steroid-reducing 
microorganism isolated from the intestine of the rat is a 
small gram-positive, strictly anaerobic bacterium. On the 
basis of its morphological and physiological characteristics, 
it has been classified as a Eubacterium and was referred to as 
Eubacterium 21,408. A pure culture of Eubacterium 21,408 
reduced cholesterol in the growth media to coprostanol with an 
efficiency exceeding 90%. This bacterium required at least 1 
mg per ml of a 5-6 double bond 3p-hydroxy steroid and bovine 
brain tissue for growth. Growth was very sparse on media 
containing 0.125 or 0.25 mg cholesterol per ml, and optimal 
growth was not obtained unless the medium contained 1.5-2 mg 
cholesterol per mI. The large amount of steroid required for 
maximal growth would indicate that cholesterol is not acting 
as a growth factor. It seems logical to assume that the 5-6 
double bond of cholesterol and plant sterols is acting as a 
hydrogen acceptor in the metabolism of the microorganism. In 
1982, Brinkley et al. (1982) isolated nine strains of 
cholesterol-reducing bacteria from intestinal contents of 
baboons. Most of these isolates required cholesterol or a 
plasmalogen found in brain for growth. 
Isolation and characterization of the cholesterol-
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reducing strains of Eubacterium have been difficult because 
these organisms failed to grow on agar media. Freier and 
Hartman at Iowa state University (1991) reported growth of a 
.:. 
pure culture of a cholesterol-reducing bacterium in medium 
that did not contain plasmalogen. This isolate is a small, 
anaerobic, nonsporing, Gram-positive rod. The isolate does not 
require cholesterol for growth, but it requires lecithin and 
seems to possess phospholipase activity. Two pure cultures 
were isolated, one from a hog sewage lagoon (HL) and one from 
stream sediment (SS). Isolate HL has been classified 
tentatively as a Eubacterium sp. 
coprostanol formation may occur by more than one pathway 
~ (Rosenfeld et al., 1967). Two major pathways have been 
postulated for formation of coprostanol from cholesterol 
(Macdonald et al., 1983). One pathway involves the 
intermediate formation of 4-5 double bond in cholestenone and 
coprostanone (Bjorkhem and Gustafsson, 1971). In the other 
pathway, cholesterol is transformed into coprostanol by the 
direct reduction of the 5-6 double bond (Rosenfeld and 
Gallagher, 1964). Rosenfeld and Gallagher (1964) incubated 
[3a-3H]-cholesterol with human feces and observed that the 
resulting coprostanol retained most of the label of C-3, 
indicating a direct reduction of the double bond. However, 
Bjorkhem and Gustafsson (1971) demonstrated that during the 
microbial conversion of [3a-3H]-cho'e=~~rD} ~u coprostanol 3a-
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tritium can be removed and then reinserted into the same 
position. Thus, it is not possible to distinguish between the 
two reduction pathways by using [3a-3H]-cholesterol as a 
substrate. Evidence for the multistep pathway has been 
presented by Bjorkhem and Gustafsson (1971) with cecal 
contents from rats and similarly by Parmentier and Eyssen 
(1974) with Eubacterium ATCC 21,408. By using [4~_3H, 4_14C]-
cholesterol as a substrate, Parmentier and Eyssen (1974) found 
that conversion to coprostanol occurred with a loss of about 
20% of the tritium; more than 70% of the tritium in 
cholesterol had been transferred to the C-6 position. The 
results. of the experiments with [4~_3H]-cholesterol leave no 
doubt that the multistep pathway is of major importance for 
coprostanol formation. 
Past Approaches for Decreasing Cholesterol in Food Products 
Much research had been conducted for several years to 
develop technologies to decrease fat and cholesterol in human 
diets. The food industry has responded with many new products. 
The technologies used can be classified as chemical, physical, 
microbiological, enzymatic, and genetic. 
The use of organic solvents to remove cholesterol and 
lipids from eggs has shown some success. Supercritical fluid 
extraction, however, has shown excellent potential. Research 
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at the university of Nebraska (Froning, 1991) has indicated 
that cholesterol and fat can be removed from dried egg yolk 
without impairing its functionality. Cholesterol content in 
dried egg yolk was decreased substantially (up. to a two-thirds 
removal) by supercritical carbon dioxide extraction. Novak et 
ale (1991) are conducting research on the removal of 
cholesterol from liquid egg yolk by using supercritical 
extraction with carbon dioxide. They reported cholesterol 
removal of up to 34 percent in liquid and up to 76 percent in 
dried egg yolk. These results indicate that supercritical 
carbon dioxide extraction may have commercial feasibility in 
the future. 
A physical process for simultaneous deodorization and 
cholesterol removal from fats and oils was reported by 
Marschuer and Fine (1989). A stream-stripping method was used 
by the Omega Source Corp., Burnsville, Minnesota to remove 93% 
of the cholesterol from milk fat. This process was thought to 
be less expensive than supercritical fluid extraction; even 
so, it is still an expensive and complicated procedure. 
Enzymes offer another alternative for decreasing the 
cholesterol content of dairy and egg products. A number of 
microorganisms have been shown to degrade cholesterol; 
however, only a few do so without accumulating any steroid 
intermediates (Arima, 1969; Masheck, 1972). Johnson and 
Somkuti (1989) reported the loss of 40% of the cholesterol 
16 
found in egg yolk preparations following treatment with 
sonicated extracts of Rhodococcus equi. Extracts of R. equi 
21107 and R. equi 33706 removed 3.3% and 3.1% of the 
cholesterol from egg yolk per min per mg of crude enzyme 
protein, respectively. Incubation of fresh cream with R. equi 
33706 extracts resulted in only a 2.4% reduction in 
cholesterol content. Cholesterol degradation by R. equi 33706 
had an optimal temperature of 40°C and an optimal pH of 8.0. 
There was no apparent requirement for divalent metal ions. 
Approximately 44% of enzyme activity was lost after a 60 min 
exposure at 60°C. Thin layer chromatographic analysis of 
cholesterol degradation products revealed only a few steroid-
like compounds, primarily 4-cholesten-3-one and 1,4-
cholestadiene-3-one. The results indicated that the 
Rhodococcus cholesterol degrading system is highly effective 
with free cholesterol in micellar solution but much less so 
with cholesterol in complex food systems, such as egg yolk and 
milk cream. 
Work is being conducted at Iowa state University to 
develop an enzymatic process to convert cholesterol to the 
coprostanol (Dehal et al., 1991). They demonstrated that 
cholesterol reductase is present in cucumber, alfalfa, and pea 
leaves. The cholesterol reductases of these plants are 
cytosolic and have an optimal pH of about 6.5. NADPH and NADH 
are the effective reducing cofactors. Preparations of 
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cholesterol reductase from alfalfa and cucumber leaves and 
cholesterol-reducing bacteria converted some cholesterol in 
homogenized milk, homogenized cream, ground beef and pork, and 
fresh and dried egg yolk to coprostanol. The conversion of 
skeletal muscle cholesterol to coprostanol also was studied 
after intravenous injections of an alfalfa cholesterol 
reductase into rats. However, at the present time, the use of 
cholesterol degrading enzymes in food remains unrealistic for 
lack of toxicological data on both enzyme extracts and 
intermediate products of cholesterol degradation. 
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SECTION 1. MECHANISM OF CHOLESTEROL REDUCTION TO COPROSTANOL 
BY CHOLESTEROL REDUCTASE 
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ABSTRACT 
The mechanism of biohydrogenation of cholesterol to 
coprostanol was studied by incubating Eubacterium sp. strain 
HL with [4-3H, 4_14C] -cholesterol as a mixture of a and J3 
isomers. In a growth medium under anaerobic conditions, 
coprostanol isolated after incubation of [4-3H, 4_14C]_ 
cholesterol retained 97% of the tritium originally present in 
cholesterol. The main part of this tritium (64%) is in the C-6 
position in coprostanol, showing that the conversion of 
cholesterol by Eubacterium HL into coprostanol involves the 
intermediate formation of 4-cholesten-3-one followed by 
reduction of the latter to coprostanol. Furthermore, [4-3H, 4-
14C]-cholesterol and coprostanone were converted efficiently to 
coprostanol. Thus, these results support the hypothesis that 
the major pathway for biohydrogenation of cholesterol by 
Eubacterium HL involves the intermediate formation of 4-
cholesten-3-one followed by reduction of the latter to 
coprostanol. 
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INTRODUCTION 
The conversion of cholesterol into coprostanol by 
intestinal microorganisms has been reported to occur by two 
different pathways (Figure 1). One involves the intermediary 
formation of 4-cholesten-3-one and coprostanone (Eyssen and 
Parmentier, 1977: Parmentier and Eyssen, 1974: Bjorkhem and 
Gustafsson, 1971). In the other pathway, cholesterol is 
transformed into coprostanol by the direct reduction of the 5-
6 double bond (Rosenfeld and Gallagher, 1964). 
In the previous work with cecal contents from rats, 
coprostanol isolated after inCUbation of [4P_3H, 4_14C] 
cholesterol retained 60% of the tritium (Bjorkhem and 
Gustafsson, 1971). Most of this tritium had been transferred 
to the C-6 position, showing that the conversion of 
cholesterol into coprostanol involves isomerization of a 5-6 
double bond to a 4-5 double bond. Rosenfeld and Gallagher 
(1964) incubated [3a-3H]-cholesterol with human feces and 
observed that the resulting coprostanol retained most of the 
label of C-3, indicating a direct reduction of the double 
bond. However, Bjorkhem and Gustafsson (1971) demonstrated 
that during the microbial conversion of [3a-3H]-cholesterol to 
coprostanol 3a-tritium can be removed and then reinserted with 
high efficiency into same position. Thus, it is not possible 
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Oxidation 
HO 
Cholesterol 
Reduction 
HO H 
Enzyme -B·-H 
V 
0 
H 
4-Cholesten-3-one 
I 
0 H 
Cop-ostanol Coprostanone 
Figure 1. Proposed multistep reaction sequence for enzymatic 
cholesterol conversion to coprostanol 
22 
to distinguish between the two reduction pathways when using 
[3a-3H]-cholesterol as a substrate. The study of Bjorkhem and 
Gustafsson invalidates the conclosion of Resenfeld and 
Gallagher. But they concluded that both pathways were of equal 
importance, whereas Parmentier and Eyssen (1974) determined 
that the indirect pathway predominated. 
Recently, Freier and Hartman at Iowa state University 
isolated a pure culture of cholesterol-reducing bacterium from 
a swine sewage lagoon sample (1991). The isolate has been 
classified tentatively as a Eubacterium sp. strain HL. This J 
isolate is a small, anaerobic, non sporing, Gram-positive rod 
that reduced almost 90% of the cholesterol in growth medium to 
coprostanol. 
In the present investigation, an attempt has been made to 
elucidate the pathways of biohydrogenation of cholesterol by 
Eubacterium HL. The reaction has been carried out with [4_3H, 
4_14C]-cholesterol as substrates in a growth medium under 
anaerobic conditions. 
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EXPERIMENTAL DESIGN 
[4-14C]-Cholesterol was purchased from Amersham Inc. 
(Arlington Heights, IL), and [4-3H]-cholesterol was prepared 
by using modifications of published procedures for preparation 
of unlabeled cholesterol. Cholesterol derivatives were 
prepared initially with deuterium label and then 
spectroscopically characterized. Tritiated materials were 
prepared by using the optimized procedures. stereochemistry of 
introduction of label was determined by nuclear magnetic 
resonance (NMR). 
[4-3H, 4-14C]-Cholesterol was incorporated into a liposome 
preparation (Freier and Hartman, 1991) and incubated for five 
days with a recently isolated monoculture of coprostanol-
producing bacteria (Eubacterium sp. strain HL). The 
coprostanol was isolated by thin-layer chromatography. The 
amount of 3H and 14C in the cholesterol substrate and 
coprostanol product was determined by dual-label counting 
techniques on the liquid scintillation counter. The results 
will be interpreted to determine the specific metabolic 
pathway for coprostanol synthesis in this bacterium. 
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EXPERIMENTAL PROCEDURE 
Materials and Methods 
Synthesis of [4-2Hl-cholesterol 
The scheme for this synthesis is shown in Figure 2. This 
sequence provides label in the 4 position as a mixture of a 
and P isomers, but is much more concise than the procedures of 
Lockley et al. (1978) to the individual stereoisomers. 
Cholesta-3,5-dienyl-3-acetate synthesis 
Cholesta-3,5-dienyl-3-acetate was prepared by the 
following procedure using a modification of the method of 
Dauben and Eastham (1950). 4-Cholesten-3-one (0.5 g, 1.30 
mmole) was dissolved in (2.5 ml, 22.7 mmole) isopropenyl 
acetate with (0.002 ml, 0.038 mmole) H2S04 • The solution was 
refluxed for 2 hours under N2 balloon attaching it. At one 
hour of reflux, the acetone formed was removed via a needle 
through the septum with an aspirator vacuum protected by a 
CaS04 drying tube. At the end of the second hour, (0.02 g, 
0.24 mmole) anhydrous sodium acetate was added to quench the 
reaction. The mixture was concentrated at reduced pressure. 
The residual bluegreen fluorescent oil was diluted with a few 
ml of chloroform and then decanted from the sodium acetate 
into about 6 ml of methanol. Additional chloroform was added 
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a 
)La 
Cholesla-3,S-dienyl-J-ocelole ~-Cho'eslen-3-ohe 
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Figure 2. synthesis of [4-2H]-cholesterol 
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to bring the oil into solution in the refluxing methanol. 
Seeding and slow cooling of this solution yielded 0.32 g (S8%) 
cholesta-3,S-dienyl-3-acetate with mp 7S.S-77°C. 
[4-2H]-cholesterol synthesis 
NaBH4 (30 mg, 0.79 mmole) and NaOH (8.S mg, 0.21 mmole) 
were added to 1 ml 1,2-dimethoxyethane, then (0.03 ml, 1.66 
mmole) of D20 was added to the mixture. Cholesta-3,S-dienyl-
acetate (4S mg, 0.11 mmole) was added to the solution~ The 
mixture was stirred for 96 hours at room temperature. The 
mixture was extracted with hexanes and washed with water four 
times. After drying with MgS04 , the hexanes was evaporated 
under reduced pressure. The residue was separated by flash 
chromatography with 1:13 (v/v) CH3CN/CH2CI2 (still et al., 
1978). The yield is 22 mg (S9%). 
Synthesis of r4-2Hl-S-Cholesten-3-one 
[4-2H]-Cholesterol (0.0064 g, 0.017 mmole) was dissolved 
in 0.S6 ml CH2CI2 • Anhydrous CaC03 powder (0.007 g, 0.070 
mmole) was added to the solution. Pyridininum chlorochromate 
(0.012 g, 0.S71 mmole) was added, and the mixture stirred for 
30 min under nitrogen at 2SoC. A saturated NaCI solution (S 
ml) then was added. The suspension was filtered and then 
thoroughly extracted with diethyl ether (10 ml) three times. 
The ether layer was filtered through anhydrous MgS04 and 
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evaporated to dryness under reduced pressure to yield [4-2H]-
5-cholesten-3-one (0.006 g; 93% yield). TLC analysis showed a 
single spot at Rf 0.55 in 4:6 (v/v) ethyl acetate: hexanes 
(Parish and Chitrokorn, 1983). 
Synthesis of [4-3H. 4_14Cl-cholesterol 
[4-3H]-Cholesterol was prepared in the same manner as [4-
2H]-cholesterol, with the sUbstitution of 0.04 ml of 50 
mCi/mmole tritiated water (Amersham Inc., Arlington Heights, 
IL) for O2°. 
The product obtained after purification by column 
chromatography on silica gel (0.040-0.063 mm) had specific 
radioactivity 8. 7x10-4 mCi/J,£l [4_14C] -Cholesterol was purchased 
from Amersham Inc. (Arlington Heights, IL) and had a specific 
radioactivity of 70 mCi/mmol. The mixture of [4-3H]-
cholesterol with [4_14C] -cholesterol is referred to as [4-3H, 
4_14C] -cholesterol. 
Proof for location of isotope in [4-2Hl-cholesterol 
Mass spectrometry was used to identify [4-2H]-cholesterol 
by using Finingan 4000 GC-MS. Deuterium content was calculated 
from M, M+1, M+2, M+3, and M+4 peaks in the mass spectra of 
the steroids. 
1H nuclear magnetic resonance (NMR) spectra were 
recorded on a Varian 500 spectrometer (operating at 500 MHz 
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for proton nuclei) by using CDCl3 or pyridine-ds as the solvent 
and tetramethylsilane (Me4Si) as the internal standard. 
13C NMR spectra were recorded on a VXR-300 spectrometer 
(operating at 75 MH~ for carbon nuclei) by using CDCl3 as both 
the solvent and internal standard. 
Deuterium NMR spectrum was recorded on a VXR-300 
spectrometer (operating at 46 MHz) using chloroform as 
solvent. 
Incubation and purification methods 
The basic cholesterol medium used throughout the study 
contained the follwing components per liter: casitone 10 g; 
yeast extract 10 g; lecithin 1 g; cholesterol 2 g; resazurin 1 
mg; sodium thioglycolate 0.5 g; and dihydrate CaClz 1 9 
(Freier and Hartman, 1991). 
[4-3H]-Cholesterol (in 95% ethanol 0.3 ~l, 2.6 ~Ci) and 
[4_14C]-cholesterol (in 95% ethanol 0.3 ~l, 2.5 ~Ci) were added 
to 1 ml of basic cholesterol medium that contains (9 ~l) 
inoculum. After incubation of the labeled sterols with 
Eubacterium HL for 5 days at 37°C under strictly anaerobic 
conditions, the sterols were extracted twice with 2 ml 
chloroform-methanol (2:1, v/v). The nonpolar phase was 
concentrated to about 100 ~l. Chromatography was performed on 
silica gel-H thin-layer plate (0.75 rom thickness) with 
hexanes:ethyl acetate (75:25, v/v) as solvent. When stained 
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with a 0.2% ethanolic solution of 2,7-dichlorofluorescein, two 
bands were observed. Bands corresponding to cholesterol and 
coprostanol were scraped into scintillation vials for isotopic 
measurements. 
Determination of isotope in different positions in coprostanol 
Determination of the position of tritium in the isolated 
coprostanol was carried out by oxidation of the coprostanol to 
coprostanone and base-catalyzed exchange of the hydrogens at 
the 2 and 4 positions. This procedure was developed by using 
deuterium and subsequently applied to the tritiated compound. 
The following procedure was adapted from the method of Parish 
and Chitrokorn (1983). Coprostanol (24 mg, 0.062 mmole) was 
dissolved in 2 ml CH2Cl2 • Anhydrous caco3 powder (25 mg, 0.25 
mmole) was added to the solution. Pyridinium chlorochromate 
(45 mg, 0.209 mmole) was added. The product was purified by 
flash chromatography with hexanes:ethyl acetate (8:2, vjv) as 
solvent. The identity and purity of the compound was further 
checked by NMR. 
Coprostanone (4 mg, 0.010 mmole) was heated at 95°C in a 
solution of sodium methoxide (15 mg, 0.28 mmole) in dioxane 
(100 ~l) and deuterated water (50 ~l, 2.8 mmole, 99.9 atom %0) 
for 24 hours. The reaction mixture was cooled and acidified 
with HCl and extracted with diethyl ether. The ether extract 
was washed with water until neutral; then the solvent was 
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dried over MgS04 and evaporated. The residue was checked with 
NMR. These conditions completely exchanged all hydrogens at C-
2 and C-4. This treatment is expected to remove all isotope in 
the C-4 position after incubation with the cholesterol-
reducing bacteria. 
The procedure was carried out on radioactive coprostanol 
in exactly the same manner, but without the NMR spectra. To 
confirm that exchange was complete, the sample was resubmitted 
to the exchange conditions. No further loss of tritium was 
observed. 
Radioactivity assay 
Tritium and 14C in the double-labeled sterols were 
determined by the two-channel ratio method in a Beckman L5-
8000 liquid scintillation spectrophotometer (Beckman 
Instruments, Inc., Palo Alto, CA) 
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RESULTS and DISCUSSION 
Proof for Location of Isotope in [4-2H]-Cho1estero1 
Determination of structure by the mass spectrum 
Mass spectra were used to help establish the structure of 
synthesized compound. Two samples of undeuterated cholesterol 
were run by solid probe at 70 eV: two samples of deuterated 
cholesterol were run in the same manner. Figure 3 shows the 
mass spectrum of cholesterol, and Figure 4 shows the mass 
spectrum of [4-2H]-cholesterol. 
The averaged results for the molecular ion region were as 
shown in Table 1. 
To determine the amounts of 2H present in the 
Table 1. 
M/Z 
384 
385 
386 
387 
388 
389 
390 
Mass data for cholesterol and [4-2H]-
cholesterol 
Normalized peak height 
Cholesterol [4-2H]-Cholesterol 
2.20 
1.01 
100.00 
29.08 
4.62 
0.48 
0.05 
0.74 
1.69 
46.52 
100.00 
47.01 
11.02 
2.39 
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isotopically labeled cholesterol mixture, it is necessary to 
correct the [4-2H]-cholesterol values for contributions from 
carbon-13. The measured values for unlabeled cholesterol are 
very close to the theoretical values calculated using natural 
abundance tables; we used the measured values for the 
following analysis. As can be seen in Table 1, the M-1(1.01) 
and M-2(2.20) peaks are small, so these fragmentation pathways 
were ignored. 
The 
The 
following solution was used: 
386 00 
387 (00+1) 01 
388 (00+2) (01+1) 02 
389 (01+2) (02+1) 03 
390 (02+2) (03+1) 04 
solution is now complete: 
386 
387 
388 
389 
390 
46.52 
(46.52x.2908)+01= 100 
(46.52x.0462)+(86.47x.2908)+02=47.01 
(86.47x.0462)+(19.72x.2908)+03=11.02 
(19.72x.0462)+( 1.29x.2908)+04= 2.39 
00=46.52 
01=86.47 
02=19.72 
03= 1.29 
04= 1.10 
Expressed as fractional abundances, the results are: 30% 
undeuterated cholesterol, 56%-01 and 13%-02. Further 
examination was carried out to obtain evidence of where 
cholesterol was labeled. 
Proton NMR assignments for cholesterol and deuterated 
cholesterol 
The 500-MHz proton magnetic resonance spectra of 
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cholesterol and deuterated cholesterol have been recorded in 
both pyridine and chloroform. 
Figures 5 and 6 show the 500-MHz 'H NMR spectra of 
cholesterol and deuterated cholesterol in chloroform. Figures 
7 and 8 show the 500-MHz 'H NMR spectra of cholesterol and 
deuterated cholesterol in pyridine. Table 2 shows chemical 
shift assignments and integration for cholesterol and 
deuterated cholesterol in CDCl3 • Table 3 shows chemical shift 
assignments and integration for cholesterol and deuterated 
cholesterol in pyridine-ds• Integration of the resonance at 
2.68-2.55 ppm in pyridine solvent and 2.33-2.18 ppm in 
chloroform solvent showed one proton each as compared with two 
protons each in the undeuterated compound. From these spectra, 
it can be concluded that one H-4 proton contributes to the 
resonance at 2.68-2.55 ppm in pyridine solvent and at 2.33-
2.18 ppm in chloroform solvent. These spectra show that 
deuterium is at C-4. But, because the C-4a and C-4~ resonances 
can not be resolved, the spectra provide no evidence of the 
stereochemistry of deuteration. 
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Table 2. 
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Proton chemical shift assignments and integral for 
cholesterol and deuterated cholesterol in CDCl3 
Proton Chemical Cholesterol 2H- Cholesterol 
locationa shift (ppm) b integral integral 
6 5.34 1.0 1.0 
3 3.51 1.0 1.0 
4a ,4e 2.26 2.1 1.2 
a Number refers to carbon number of cholesterol, a to 
axial, and e to equatorial. 
b Assignments from the reference of Barry et al (1973). 
Table 3. Proton chemical shift assignments and integral for 
cholesterol and deuterated cholesterol in pyridine-
ds 
Proton Chemical Cholesterol 2H- c holesterol 
locationa shift (ppm) b integral integral 
6 5.43 1.0 1.0 
3 3.85 1.0 0.9 
4a, 4e 2.62 2.1 1.0 
2e 2.11 1.0 0.9 
7a, 7e 2.03 2.0 2.0 
la, le, 2a 1.80 2.9 2.9 
a Number refers to carbon number of cholesterol, a to 
axial, and e to equatorial. 
b Assignments from the reference of Sawan et al (1979). 
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13C Nuclear magnetic resonance spectra of cholesterol and 
deuterated cholesterol 
Although proton NMR gave us much information in 
structural and conformational studies of cholesterol and 
deuterated cholesterol, the overlap of many lines with closely 
similar chemical shifts causes great difficulty in explaining 
the spectra. This is one thing, the other thing is that so far 
I did not show strong evidence for the deuterium position. 
13C NMR spectra are in general much more informative than 
1H NMR spectra for structural analyses of complex molecules. 
13C NMR spectra were recorded on a VXR-300 spectrometer 
(operating at 75 MHz for carbon nuclei) using CDCl3 as both 
the solvent and internal standard (77.06 ppm) with proton 
decoupling. The chemical shifts are shown in Table 4. They are 
also displayed in Figure 9 and Figure 10. 
When hydrogen is replaced by deuterium the carbon-4 
undergoes an appreciable upfield shift of about 0.2 ppm per D 
atom (Silverstein et al., 1981). In this experiment, isotope 
effect resulted in a slight upfield shift of C-4 absorption 
(0.25 ppm). In addition, the carbon-4 resonance appears as 
1:1:1 triplet due to the spin coupling of deuterium (I=l) with 
carbon. The resonances of the carbons-3, 5, and 6 are 
broadened somewhat due to unresolved carbon-deuterium coupling 
(data not shown). Figure 11 shows an expansion of the carbon-4 
region. The coupling constant is 18 Hz. A normal coupling 
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constant Table 4. 13C Chemical shifts for cholesterol and 
deuterated cholesterol in CDCl3 solvent in ppm relative to CDCl3 at 77.06 ppm 
Deuterated 
Carbon cholesterol Cholesterol a Cholesterolb 
1 37.3 37.3 37.5 
2 31.7 31.6 31.6 
3 71.S 71.6 71.3 
4 42.2, 42.0, 41.7 42.3 42.4 
5 140.S 140.S 141.2 
6 121.S 121.6 121.3 
7 32.0 31.9 32.0 
S 32.0 31.6 32.0 
9 50.2 50.1 50.5 
10 36.6 36.5 36.5 
11 21.1 21.1 21.2 
12 2S.3 2S.2 2S.3 
13 42.4 42.2 42.4 
14 56.S 56.S 56.9 
15 24.3 24.3 24.3 
16 39.S 39.S 40.0 
17 56.2 56.2 56.5 
lS 11.9 11.9 12.0 
19 19.4 19.4 19.4 
20 35.S 35.S 35.S 
21 lS.S lS.S lS.S 
22 36.2 36.2 36.4 
23 23.9 23.9 24.1 
24 39.6 39.5 39.6 
25 2S.1 2S.0 2S.0 
26 22.6 22.6 22.5 
27 22.9 22.S 22.S 
a Assignments made in this work. 
b Assignment from Breitmaier and Voelter (19S7) • 
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deuterium coupled to 13C is 18.5 Hz (Silverstein et al., 1981). 
The introduction of a second deuterium on the carbon-4 
usually results in a disappearance of the carbon-4 signal, or 
5 multiplicities. However, appreciable upfield shifts and line 
broadening are observed at the carbons-3, 5, maybe carbon-6 
(Leyden and Cox, 1977). In this experiment, line broadening 
was observed at C-3, 5 and 6. Interestingly, only a very small 
(about 10%) residual DO signal remains for C-4. This is in 
contrast to the 30% DO seen in the mass spectrum. 
Deuterium NMR spectrum 
To confirm the above evidence and to find whether 
deuterium was present at a position other than C-4, Deuterium 
NMR spectrum of deuterated cholesterol was recorded at 46 MHz 
in chloroform (Figure 12). The chemical shifts (2.24 ppm) 
observed for deuterium are the same as seen for the C-4 proton 
(2.26 ppm) in Figure 5 and 6. 
From these spectra, it can be concluded that only one 
proton is attached to C-4 position. In other words, one 
deuterium was labeled on H-4. However, there is no strong 
evidence to show the deuterium is axial or equatorial. This 
question remained to be answered. 
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The nuclear overhauser effect (NOEl in structural analysis of 
deuterated cholesterol 
NOE experiments are used to provide information about 
molecular geometries. Experimentally, the method involves the 
saturation of one signal in the spectrum and observation of 
changes in the intensities in the other signals. The magnitude 
of the intensity changes depend upon internuclear distances 
between the nuclei concerned. These intensity changes arise 
from perturbations of the the relaxation processes, which lead 
to thermal equilibrium between the spin states. The relaxation 
of a given nucleus is affected by all surrounding nuclei and 
the relaxation from other nuclei is dominated by short range 
interactions and is proportional to r-6 where r is the distance 
separating the nuclei. 
Two dimensional NMR experiment (NOESY) Two 
dimensional NOE spectra allow the measurement of fairly weak 
NOE effects. The 2D NOE experimental data are presented in 
Table 5. Figure 13 represents 2D NOE spectrum of deuterated 
cholesterol. Some of the relevant assignments are presented on 
the structure. From the spectrum and data, I note that H-4 has 
a weak NOE with C-19, a modetate NOE with H-3 and the 
strongest NOE with H-6. That means that some deuterium is in 
the axial position (P). Deuterium in the equatorial position 
H-4 should have the strong NOE with C-19 and a weaker NOE with 
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Table 5. 
Signal 
C-6 
C-3 
C-19 
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Two dimensional NOE spectroscopy (NOESY), 
cross peak to C-4 (2.6 ppm) 
Shift Relative Distancea 
(ppm) intensity (A) 
5.4 1 3.30 
3.8 0.3 2.49 
1.0 0.2 2.24 
a Distance is calculated by PCMODEL using the mmx force field. 
H-3, H-6. To determine the ratio of axial to equatorial 
deuterium, a quantitative measure of the NOE values is needed. 
One dimensional NMR experiment for deuterated cholesterol 
Because NOESY allowed us to establish that both stereochemical 
dispositions of deuterated cholesterol were present, I hoped 
that one dimensional (10) NOE spectroscopy could establish the 
ratio of stereochemical dispositions of deuterated cholesterol 
with more confidence. The 10 NOE results are presented in" 
Table 6. 
Irradiation at C-4 of deuterated cholesterol led to 
enhancement at the C-19 methyl group in an amount only 38% of 
that seen with unlabeled cholesterol. This observation 
suggests that 62% of the 4P position may bear deuterium. Mass 
spectral data show 0.82 deuterium in the cholesterol 
molecules; in other words, 76% of deuterium is in the axial 
position (P). However, irradiation at C-19, the inverse 
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experiment, led to 76% as much NOE to C-4 in the deuterated 
compound as compared with the unlabeled cholesterol. This 
observation corresponds to 65% of the deuterium in the ~ 
position, assuming the mass spectrum data are correct. Thus, I 
estimate about 65%-76% of the deuterium is in the ~ position 
(or about ~:a=2:1). The problem is that the H-4a and H-4~ 
peaks are not separate in 'H NMR spectrum of cholesterol. If 
H-4a and H-4~ can be resolved, I could determine directly how 
much deuterium is in an axial and how much in an equatorial 
position. 
Table 6. One dimensional NOE spectroscopy 
Irradiated Shift Signal Shift 2H-Cholesterol Cholesterol 2HJH Distancea 
at (ppm) (ppm) enhancement(%) enhancement(% ) (A) 
C-4 2.6 C-6 5.4 4.58 6.69 0.68 3.30 
C-4 2.6 C-19 1.0 0.94 2.49 0.38 2.24 
C-4 2.6 C-3 3.8 1.76 2.83 0.62 2.49 
C-19 1.0 C-3 3.8 0.29 0.23 1.62 
C-19 1.0 C-4 2.6 2.80 3.70 0.76 2.24 
C-19 1.0 C-6 5.4 0.13 0.03 4.30 
a Distance is calculated by PCMODEL using the mmx force field. 
One dimensional NOE experiment for [4-2H]-5-cholesten-3-
one Figure 14 shows the 300-MHz 'H NMR spectrum of 5-
cholesten-3-one in CDCI3 • Examination of this spectrum yielded 
the complete assignments for the protons on carbon atom number 
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4 (referred to as Hb and Hc). Doublets are seen at 2.79 ppm 
and 3.25 ppm with a geminal coupling constant 16.5 Hz. These 
peaks were assigned to 4a and 4P by NOE spectroscopy. Figure 
15 shows the 10 NOE spectrum. On irradiation at C-19 (referred 
to as d, 1.18 ppm), a strong NOE was seen to Hb (3.25 ppm). On 
the other hand, no NOE effects were observed at Hc (2.79 ppm). 
Consequently, Hb is assigned to the axial H-4P and Hc is 
assigned to the equatorial H-4a. Thus, the amount of deuterium 
in an axial and equatorial position can be determined in this 
compound simply by integration. 
Table 7 shows chemical shift assignments and integration 
for 5-cholesten-3-one and [4-2H]-5-cholesten-3-one. 
Integration of the 3.25 ppm doublet shows a 58% decrease 
because of deuterium being located at the axial position of C-
4, and integration of the 2.79 ppm doublet shows a 28% 
decrease because of deuterium being located at the equatorial 
position of C-4. Therefore, 67% (O.58/{O.58+0.28)} of the 
deuterium is in the p position. This value compares favorably 
with the two previous estimates of 65% and 76% which were 
based on NOE on the cholesterol itself. This third estimate, 
thus provides more evidence for stereochemical location of 
d4~tex~amsaunaeQteTheemeahotemeBroa~swh~cbv~aesea~ mat~metetbe 
value of 17% derived from mass spectral data (30%DO-13%D2). 
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Figure 15. 10 NOE spectrum of 5-cholesten-3-one 
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Table 7. Chemical shift assignments and integration for 5-
cholesten-3-one and [4-2H]-5-cholesten-3-one 
Proton Chemical IntegralC Integrald 
locationa shift (ppm) b 
6 (6a) 5.36 1.0 1.0 
4f3 (4b) 3.25 1.0 0.42 
4a (4c) 2.79 1.0 0.72 
a Number refers to carbon number in cholesterol 
b with respect to internal TMS. 
C Relative area under peak for 5-cholesten-3-one. 
d Relative area under peak for [4-2H]-5-cholesten-one. 
Incubation studies 
Determination of time required for maximal reduction of 
cholesterol by Eubacterium HL 
Table 8 summarizes the changes in [4-3H, 4_14C]-
cholesterol as the fermentation of Eubacterium HL proceeded. 
The maximal yield of reduced sterol (coprostanol) was obtained 
in 5 days when almost 90% of cholesterol was converted into 
coprostanol (Figure 16). 
As shown in Table 8, the isolated coprostanol had 
retained 97% ± 2.5% of the tritium originally present in 
cholesterol. 
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Table 8. Conversion of [4-3H, 4_14C] -cholesterol to 
coprostanol by Eubacterium HL8 
Measurement 
Cholesterol 
disappearance 
Coprostanol 
appearance 
Backgroundd 
Day of 
incubation 
OC 
1 
2 
3 
4 
5 
6 
7 
OC 
1 
2 
3 
4 
5 
6 
7 
3H 
(dpm) 
10743 
10400 
10596 
7380 
1922 
1716 
1332 
1519 
50 
202 
475 
4676 
8770 
9108 
8613 
8187 
49 
14C YieldD 
(dpm) (%) 
9735 100 
9511 98 
9282 95 
6432 66 
1794 18 
1511 16 
1142 12 
1323 13 
22 0 
176 1.8 
444 4.5 
4433 46 
8170 84 
8561 89 
8058 83 
7932 82 
19 
a Each value is an average of two measurements. 
3H/ 14C 
1.10 
1.09 
1.14 
1.14 
1.07 
1.13 
1.16 
1.15 
1.15 
1.07 
1.05 
1.07 
1.06 
1.06 
1.03 
b The first set of numbers (100-13) refers to percentage of 14C 
labeled cholesterol that remains in the media; the second set 
of numbers (0-82) refers to percentage of 14C label found in 
coprostanol. 
C Time 0 indicates [4-3H, 4_14C] -cholesterol isolated from an 
uninoculated blank. 
d Background refers to the background of a Beckman L5-8000 
liquid scintillation spectrophotometer. Background was not 
subtracted from other values in the table. 
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Figure 16. Percentage change in cholesterol and 
coprostanol concentration as the fermentation 
proceeded. 
Determination of the products of Eubacterium HL other than 
coprostanol 
According to Bjorkhem and Gustafsson (1971), 4-cholesten-
3-one and coprostanone might be intermediates in the 
conversion of cholesterol into coprostanol. Thereforei I 
investigated whether Eubacterium HL was able to convert 
cholesterol into 4-cholesten-3-one and coprostanone. The 
procedures used in this experiment were same as before. The 
only difference was that to the organic extract was added 
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Table 9. Products of cholesterol produced by Eubacterium HL 
compound 3H 14C 3H/14C 3H 
(dpm) a (dpm) a retained (%) 
BlankD 4375 4009 1.09 100 
coprostanol 3935 3676 1. 07 98 
4-Cholesten-3-one 55 30 
·Coprostanone 52 24 
BackgroundC 49 19 
a each value of an average of two measurements. 
b Blank indicates [4-3H, 4_14C] -cholesterol isolated from the 
uninoculated blank after 5 days of incubation. 
C Background refers to the background of a Beckman L5-8000 
liquid scintillation spectrophotometer. Backgound was not 
subtracted from other values in the table. 
authentic 4-cholesten-3-one (Kodak Inc., Rochester, NY) and . 
coprostanone (Steraloids Inc., Wilton, NH) (each 1 mg/ml). The 
TLC plates of the extracts of incubations described in the 
previous section only showed two bands--one for cholesterol 
and one for coprostanol. The data are presented in Table 9. 
Eyssen et al. (1973) reported that production of 
coprostanol on a preparative scale by Eubacterium 21,408 
always yielded small amounts of 4-cholesten-3-one and 
coprostanone. Their data support the indirect pathway for 
formation of coprostanol. In my experiment, I demonstrated, 
however, that coprostanone and 4-cholesten-3-one, if formed, 
are not released, or are further transformed more rapidly than 
is cholesterol to coprostanol. Thus, this observation suggests 
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that cholesterol is converted to coprostanol as a direct 
reduction or more likely as a multistep reduction without 
release of intermediates from the enzyme. 
Determination of isotope in different position in coprostanol 
To determine whether the label had been retained at C-4 
or transferred to C-6, I oxidized coprostanol to coprostanone 
and exchanged the C-4 and C-2 hydrogens with base. I worked 
out conditions, as before, by using deuterated materials. 
In the deuterium exchange experiment, the 13C NMR spectra 
confirmed complete deuteration at the expected position(s), C-
4 (non radioactive coprostanone was used rather than 
radioactive coprostanone). Figure 17 shows chemical shifts for 
coprostanone and deuterated coprostanone in CDCl3 solvent. 
Figure 18 shows expansion of chemical shifts for coprostanone 
and deuterated coprostanone in CDCl3 solvent. The peaks 
corresponding to C-2 and C-4 were deuterated completely. 
Table 10 summarizes the results of localization of 3H in 
coprostanol isolated from incubations with Eubacterium HL. 
Treatment with pyridinium chlorochromate did not remove any of 
the 3H, whereas base-catalyzed exchange of coprostanone into 
deuterated coprostanone with sodium methoxide and deuterated 
water removed about 36% of the 3H• Therefore, it was concluded 
that the main part of 3H (64%) in coprostanone was situated in 
the C-6 position. 
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Figure 18. The expansion of chemical shifts for 
coprostanone (A) and deuterated coprostanone 
(B) showing that C-2 and C-4 disappeared 
because of deuterium sUbstitution 
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Table 10. Localization of 3H in coprostanol isolated from 
incubations with Eubacterium HL 
Compound 3H 14C 3H/ 14C 3H 
(dpm) a (dpm) a retained 
Coprostanol 2810 2620 1.07 100 
Coprostanone 2086 1963 1. 06 99 
Deuterated-
coprostanone 688 1031 0.67 63 
Re-deuterated 
coprostanone 373 535 0.69 65 
a Each value is an average of two measurements 
(%) 
Resubmission of the exchanged coprostanone to the sodium 
methoxide for a further 96 hours caused no more change in 
3H/ 14C ratio, indicating that exchange was completed and not 
just slowed by a tritium isotope effect. 
This ratio of about 2:1 for C-6:C-4 matches the 2:1 ratio 
of p:a seen for the deuterium at C-4. If tritium goes on in 
the same ratio, that would seem to be the maximal C-6:C-4 
ratio possible. This data. indicates that no solvent exchange 
occurs during proton transfer from C-4 to C-6 by the enzyme. 
Whereas an incomplete exchange of coprostanone also would 
explain such a high retention of label, I believe the re-
deuteration of coprostanone has ruled out that possibility. 
The results of the present work are consistent with the 
presence of a pathway from cholesterol to coprostanol 
involving 4-cholesten-3-one and coprostanone as intermediates. 
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From studies on biohydrogenation of [4~_3H, 4-14C]-cholesterol 
by Eubacterium ATCC 21,408, Parmentier and Eyssen (1973) 
concluded that significant amounts of tritium could be removed 
from the C-4 position and that ~ore than 70% of this tritium 
was transferred to the C-6 position of coprostanol. This 
observation suggested that the major pathway for production of 
coprostanol by Eubacterium 21,408 involves the intermediate 
formation of 4-cholesten-3-one. The present investigations 
with a pure culture of Eubacterium HL extend these 
observations. Isomerization of a 5-6 double bond to a 4-5 
double bond by a mechanism involving transfer of the C-4 H to 
the C-6 position during conversion of cholesterol into 
coprostanol indicated that Eubacterium HL followed the so-
called indirect pathway with formation of 4-cholesten-3-one. 
I observed that nearly 36% of 3H remained in the C-4 
position, whereas 64% of 3H was transferred to the C-6 
position of coprostanol. These two values are close to the 
deuterium distribution in [4-2H]-cholesterol reported earlier 
(67% in an axial position, 33% in an equatorial position). 
The indirect pathway hypothesis for formation of 
coprostanol implies that the microorganism could possess two 
enzyme systems: one that converts cholesterol into 4-
cholesten-3-one, and the other that reduces 4-cholesten-3-one 
to coprostanol. It should be mentioned that production of 
coprostanol on a large scale did not yield small amounts of 4-
64 
cholesten-3-one in this experiment. 
Reduction of coprostanone by Eubacterium HL 
According to Eyssen et ale (1973), Eubacterium ATCC 
21,408 was capable of converting cholesterol into coprostanol; 
it also could convert 4-cholesten-3-one and coprostanone into 
coprostanol. I investigated, therefore, whether Eubacterium 
HL was able to reduce coprostanone to coprostanol in basic 
cholesterol growth medium described earlier. 
Radioactive coprostanone was incubated with Eubacterium 
HL for 3 days in basic cholesterol growth medium at 37°C. The 
procedure used in this experiment were same as before. The 
data are presented in Table 11. 
This experiment demonstrated that Eubacterium HL was able 
to reduce coprostanone into coprostanol. This experiment, 
together with the fact that more than 60% of 4-3H of 
cholesterol was transferred by an intramolecular shift to the 
C-6 position of coprostanol during the process of 
biohydrogenation, tends to favor the theory of the indirect 
pathway for formation of coprostanol. 
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Table 11. Reduction of coprostanone by Eubacterium HL 
compound 3H 14C 3H/ 14C 
(dpm) a (dpm) a 
Coprostanone blankb 1139 1102 1.05 
Cholesterol 52 20 
Coprostanol 617 590 1.05 
Coprostanone 330 320 1.03 
BackgroundC 46 18 
a Value is an average of 4 measurements. 
b Coprostanone blank indicates coprostanone isolated from the 
uninoculated blank after 3 days of incubation. 
C Background indicates the background of a Beckman L5-8000 
liquid scintillation spectrophotometer. Background was not 
subtracted from other values in the table. 
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SUMMARY 
The primary purpose of this research was to determine the 
pathway of cholesterol reduction to suggest whether one or 
more protein molecules are responsible for cholesterol 
reductase activity in Eubacterium sp. strain HL. 
A significant conversion of [4-3H, 4_14C] -cholesterol to 
coprostanol was observed after inCUbation with Eubacterium HL 
isolated by Freier and Hartman (1991) in growth medium under 
anaerobic conditions. The coprostanol synthesized from [4-3H, 
4-14C]-cholesterol by incubation of Eubacterium HL retained 97% 
of the tritium originally present in cholesterol. More than 
60% of the tritium in cholesterol, however, had been 
transferred to the C-6 position in coprostanol. Furthermore, 
Eubacterium HL was capable of converting cholesterol to 
coprostanol, and of converting coprostanone to coprostanol. 
These observations support the hypothesis that t he major 
pathway for biohydrogenation of cholesterol by Eubacterium HL 
involves the intermediate formation of 4-cholesten-3-one 
followed by reduction of the latter to coprostanol. The 
conclusions from the present investigations are in agreement 
with a previous study that showed production of coprostanol by 
Eubacterium 21,408 involves the intermediate formation of 4-
cholesten-3-one (Parmentier and Eyssen, 1973). 
I too have demonstrated that the multistep mechanism is 
67 
followed by the cholesterol reductase of Eubacterium HL, and 
developed a method that may be used to screen other sourses of 
cholesterol reductase for their enzymes for the mechanisms. 
There is no evidence that a single step pathway is ever 
followed for this transformation. It should be mentioned that 
conversion of [4-3H, 4_14C]-cholesterol to coprostanol by 
incubation with Eubacterium HL in growth medium did not yield 
detectable amounts of 4-cholesten-3-one and coprostanone. This 
is an important result for future research. Use of cholesterol 
reductase to decrease the cholesterol content of foods will 
require transfer of a gene(s) coding for cholesterol reductase 
into safe, easy-to-grow organisms, such as E. coli, yeast, or 
lactobacillus, for the production of sufficiently large 
amounts of the reductase. Cloning of genes for commercial 
production of cholesterol reductase will be several-fold 
easier if only one gene rather than several genes are involved 
in the reduction of cholesterol to coprostanol. 
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GENERAL SUMMARY 
The public has an abiding interest in the relation of 
diet and health. A recent publication from the National 
Research Council/National Academy of Sciences with the title 
"Diet and Health" (1989) points up this continuing public 
interest and concern about the relationships of these two 
sUbjects. The "cholesterol scare" has been a major factor 
causing public concern about consuming foods derived from 
animals. My research group expect to develop the technology to 
use a purified enzyme to safely produce milk, egg, and meat 
that has substantially lower concentrations of cholesterol. 
Knowledge of the characteristics of the cholesterol reductase 
will be highly useful for subsequent development of protocols 
for using the enzyme to decrease the cholesterol content of 
animal products used as food. 
Researchers at Iowa state University (Freier and Hartman, 
1991) have developed a strain of bacteria named Eubacterium 
sp. strain HL that someday may allow people to eat high-
cholesterol foods without-absorbing most of the cholesterol. 
Species of Eubacterium are normal inhabitants of the human 
colon, which should minimize concerns about adding a 
constituent enzyme of the bacteria to foods that will be 
consumed by people. 
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The conversion of.cholesterol into coprostanol by 
intestinal microorganisms has been reported to occur by means 
of two different pathways. From studies on biohydrogenation of 
[4-3H, 4-14C]-cholesterol by Eubacterium HL, the mechanism of 
indirect pathway is of major importance for coprostanol 
formation. As is apparent, the present experiments do not 
provide direct evidence for the participation of mechanism of 
direct pathway in coprostanol formation. This could have 
implications in our future goals of isolating the cholesterol 
reductase and cloning the gene for commercial production of 
cholesterol reductase. 
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APPENDIX 
Interpretation of One Dimensional NOE Experiment 
Based on mass spectral data (p.31), total deuterium in 
cholesterol molecules can be calculated: 
01+2(02)=56%+2(13%)=0.82. 
Irradiation at C-4 of deuterated cholesterol (p.51) led 
to 0.94% enhancement at C-19 compared to 2.49% enhancement of 
unlabeled cholesterol. That means 62% decrease due to 
deuterium in 4P position. Therefore, 0.62/0.82=76% of the 
deuterium is in the 4P position, and 24% of deuterium in 4a 
position. 
When C-19 was irradiated, it led to 76% as much NOE at C-
4 in deuterated cholesterol was seen as compared to the 
unlabeled cholesterol. How to interpret this value? From mass 
spectral data and 10 NOE, we know deuterium has two different 
positions at C-4 in deuterated cholesterol. So irradiation at 
C-19 led to different NOE at C-4 of deuterated cholesterol. 
A. 2H a gives 200% NOE vs unlabeled cholesterol 
B. 2H P gives 0% NOE vs unlabeled cholesterol 
C. unlabeled C-4 gives 100% vs unlabeled cholesterol 
The solution is complete: 
2A+C=0.76 
80 
A+B+C=l 
A+B=0.82 (based on mass spectral data) 
Now we get: A=0.29 
B=0.53 
C=0.18 
Therefore, B/(A+B)=65% of the deuterium is in the 4~ 
position, and A/(A+B)=35% of the deuterium is in the 4a 
position. 
From these experiment, we think about 65-76% of the 
deuterium is in the 4~ position, although these two values are 
not very accurate. 
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